ClinicalTrials.gg
CompletedNCT01822288Updated Feb 23, 2022

The Impact of Hormone Therapy on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder

A Phase 4 interventional study of Tibolone and Estradiol & medroxyprogesterone acetate in Menopausal Syndromes, sponsored by Far Eastern Memorial Hospital. Completed at 1 site in Taiwan. Open to female participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-02-23.

Sponsored by Far Eastern Memorial Hospital · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
125
Allocation
Non-randomized
Ages
40 Years to 70 Years
Sex
Female
01

Study summary

Menopausal syndromes includes somatic symptom, psychosomatic symptoms, sexual dysfunction and even urinary symptoms. Hormone therapy (HT) is widely used for controlling menopausal symptoms. Common HT for menopausal syndrome with intact uterus includes tibolone, estradiol valerate (E2V) 1mg \& medroxyprogesterone acetate (MPA) 2.5 mg, and conjugated equine estrogens \& MPA.

However, only a few literatures mentioned about the therapeutic effect of tibolone, but lack of comparison research about their therapeutic effect on somatic symptoms, psychosomatic symptoms, sexual dysfunction and even urinary symptoms. The knowledge of the above therapeutic effects should be important for choosing a suitable medication. Therefore, the aim of this study is to assess the therapeutic effect on somatic symptoms, psychosomatic symptoms, sexual dysfunction and even urinary symptoms between tibolone and E2V/MPA.

02

Conditions studied

  • Menopausal Syndromes

Keywords

  • Menopause
  • Tibolone
  • Estradiol
  • Hormone therapy
03

In context

Lead sponsor

Far Eastern Memorial Hospital is the lead sponsor of 260 studies on the registry; 40 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All female patients with intact uterus who seek for medical treatment for menopausal syndrome

Exclusion criteria

Exclusion Criteria:

  • patients with gynecologic or breast cancers
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
125 participants (actual)

Study arms

  • Experimental
    Tibolone group

    Tibolone (2.5 mg per day)for 12 consecutive weeks. Tibolone should be paid by patient herself, and does not cover by Taiwan Government health insurance.

    Drug: Tibolone

  • Active comparator
    Conventional hormone therapy group

    Estradiol valerate (E2V) 1mg \& medroxyprogesterone acetate (MPA) 2.5 mg per day for 12 consecutive weeks, and this drug is paid by Taiwan Government health care insurance.

    Drug: Estradiol & medroxyprogesterone acetate

Interventions

  • Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)

  • DrugEstradiol & medroxyprogesterone acetate

    Drug pages: Estradiol · Medroxyprogesterone Acetate

    Estradiol \& medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug

06

What researchers measure

Primary outcomes

  1. Menopausal symptoms

    To clarify any difference of reduction in menopausal symptom scores between these two groups

    Time frame: 12 weeks

Secondary outcomes

  1. sexual function

    To clarify any difference of improvements of sexual function scores between these two groups

    Time frame: 12 weeks

  2. lower urinary tract symptoms

    To clarify any difference of improvements of lower urinary tract symptoms scores between these two groups

    Time frame: 12 weeks

  3. psychosomatic symptoms

    To clarify any difference of improvements of psychosomatic symptoms scores between these two groups

    Time frame: 12 weeks

07

Study locations

1 site
  • Far Eastern Memorial Hospital
    Banqiao, New Taipei 220, Taiwan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2012 to primary completion in Jul 2021, 103 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2012
First posted
Apr 2, 2013
StartActual
Nov 16, 2012
Primary completionActual
Jul 8, 2021
CompletionActual
Aug 26, 2021
Last update
Feb 23, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01822288
Responsible party
Sheng-Mou Hsiao (Chief, Department of Obstetrics & Gynecology, Far Eastern Memorial Hospital) — Principal investigator
First posted
Apr 2, 2013
Start date
Nov 16, 2012
Primary completion
Jul 8, 2021
Completion
Aug 26, 2021
Last update
Feb 23, 2022

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tibolone

Start the discussion